1. Home
  2. Volume 20 Number 1, February 2020
  3. DASOPANG

Potential side effects of medicine on patients with tuberculosis fixed-dose combination in dr. Pirngadi Hospital, Medan

EVA SARTIKA DASOPANG, FENNY HASANAH, IDA FAUZIAH, SALMAN SALMAN, TEDY KURNIAWAN BAKRI

Abstract


Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, which by only using a few new antibiotics, can kill the bacteria. Tuberculosis treatment has several stages, namely intensive and advanced stages. Compliance with the use of OAT is an imported factor in the success of TB treatment. The use of many drugs can cause side effects that result in patients stopping treatment when it creates the TB treatment process to fail. Improved adherence can do by using a fixed-dose combination OAT. In the intensive phase, the patient will get a fixed-dose combination containing a mixture of four antibiotics. The purpose of this study is to evaluate the potential side effects that occur during fixed-dose combination OAT treatment at an intensive stage and see the level of compliance of patients taking TB drugs. Observational sampling in TB patients was taking OAT at an acute stage by looking at side effects that arise during treatment and then analyzed using statistics and algorithm Naranjo. The results showed the most common potential side effects for fixed-dose combination OAT in the intensive stage were itching, headache and nausea with a percentage of 72% each, joint pain 45%, stomach pain 36.4%, lack of appetite and rashes 27.3% each and reddish color in the urine 18.2%. The results of the analysis using Naranjo logarithm obtained results eight, which means the side effects might cause due to the use of the drug. The results of patient compliance achieved a 100% compliance rate

Keywords


fixed-dose combination, anti-tuberculosis drugs, potency, side effect

References


World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization.

O'Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J., & Berry, M. P. 2013. The immune response in tuberculosis. Annu. Rev. Immunol. 31 475-527

Hiswani, M. 2004. Tuberkolosis merupakan penyakit infeksi yang masih menjadi masalah kesehatan masyarakat. e-USU Repos. Univ. Sumatera Utara.

Kemenkes RI. 2018. Tuberkulosis ( TB ).

Kurniawan, N. ’, HD, S. R. and Indriati, G. 2015. Faktor-faktor yang mempengaruhi keberhasilan pengobatan tuberkulosis paru. JOM 2(1) 729-741

Safa, M., Tabarsi, P. and Sharifi, H. 2011. Pattern of tobacco consumption among TB patients in a tuberculosis referral center. Tanaffos 10(2) 50.

Schneidera, N. K. & Novotnya, T. E. 2007. Addressing smoking cessation in tuberculosis control. Bull. World Health Organ. 85 820-821

Puspitasari, P. 2014. Profil pasien tuberkulosis paru di Poliklinik Paru RSUP Prof. Dr. R.D. Kandou Manado. E-Clinic 2 1–9.

Nurjana, M. A. 2015. Faktor risiko terjadinya tuberculosis paru usia produktif (15-49 Tahun) di Indonesia. Nurjana, M. A. (2015). Faktor risiko terjadinya Tuberculosis paru usia produktif (15-49 tahun) di Indonesia. Media Penelitian dan Pengembangan Kesehatan 25(3) 163-170.

Rusnoto, R, Rahmatullah P., Udiono, A. 2008. Faktor-faktor yang berhubungan dengan kejadian Tb paru pada usia dewasa (Studi kasus di Balai Pencegahan Dan Pengobatan Penyakit Paru Pati). Jurnal Epidemiologi

WHO. 2016. WHO treatment guidelines for drug-resistant tuberculosis: World Health Organization.

Belhekar, M. N., Taur, S. R. and Munshi, R. P. 2014. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J. Pharmacol. 46(1) 117

Blomberg, B., Spinaci, S., Fourie, B. and Laing, R. 2001. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 79 61-68

Sari, I. D., Yuniar, Y., and Syaripuddin, M. 2014. Studi monitoring efek samping obat antituberkulosis fsc kategori 1 di Provinsi Banten dan Provinsi Jawa Barat. Media Penelitian dan Pengembangan Kesehatan 24(1), 28-35

Arbex, M. A., Varella, M. de C. L., Siqueira, H. R. de and Mello, F. A. F. de. 2010. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J. Bras. Pneumol. 36 626–640.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling tuberculosis in the United States. Am. J. Respir. Crit. Care Med. 172(9) 1169-1227.

Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. 2003. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 167(11) 1472-1477.

Athira, B., Cs, M. & Jyothi, E. 2015. A study on adverse drug reactions to first line antitubercular drugs in DOTS therapy. Int. J. Pharmacol. Clin. Sci. 4(1) 7-11

Joddy Sutama Putra, R., Achmad, A. and Rachma Pramestutie, H. 2017. Kejadian Efek Samping Potensial Terapi Obat Anti Diabetes Pada Pasien Diabetes Melitus Berdasarkan Algoritme Naranjo. Pharm. J. Indon. 2(2) 45-50.

Dasopang, E. S., Harahap, U. and Lindarto, D. 2015. Polipharmacy and Drug Interactions in Elderly Patients with Metabolic Diseases. Indon. J. Clin. Pharm. 4(4) 235-241

Munro, S. A., Lewin, S. A., Smith, H. J., Engel, M. E., Fretheim, A., and Volmink, J. 2007. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 4(7) e238

Xu, W., Lu, W., Zhou, Y., Zhu, L., Shen, H., and Wang, J. 2009. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: A qualitative and quantitative study. BMC Health Serv. Res. 9(1) 169.


Full Text: PDF

DOI: 10.24815/jn.v20i1.15285

Refbacks

  • There are currently no refbacks.